SRINAGAR: Jammu and Kashmir recorded 11,959 tuberculosis (TB) cases in 2025, according to data placed in the Lok Sabha by the Ministry of Health and Family Welfare. The figures were presented as part of a statement on national disease control programmes, which also shows large-scale screening for non-communicable diseases and a decline in HIV incidence across the country.
The data shows that TB notifications in Jammu and Kashmir have remained broadly stable over the past five years, with 10,826 cases in 2021, 11,804 in 2022, 11,754 in 2023, 12,200 in 2024 and 11,959 in 2025, according to information compiled under the TB Mukt Bharat Abhiyan (National TB Elimination Programme).
At the same time, screening under the National Programme for Prevention and Control of Non-Communicable Diseases (NP-NCD) has covered millions in the Union Territory. The government informed Parliament that in Jammu and Kashmir 53,76,866 people have been screened for hypertension, 53,69,282 for diabetes, 51,52,554 for oral cancer, 24,37,688 for breast cancer and 16,54,581 for cervical cancer under population-based screening initiatives.
The statement also reported progress in HIV control in the region. For Jammu and Kashmir and Ladakh, the HIV incidence declined from 0.020 per thousand uninfected population in 2020 to 0.010 in 2024, while AIDS-related mortality fell from 0.017 to 0.009 per thousand population during the same period. The number of people receiving anti-retroviral treatment at government facilities rose from 2,925 in 2020-21 to 4,174 by December 2025.
The data was presented in reply to a starred question in Parliament regarding the implementation of national disease control programmes for communicable and non-communicable diseases, including HIV/AIDS, tuberculosis, cancer, leprosy and vector-borne diseases.
The Union government informed Parliament that health is primarily a state subject, while the Centre supplements state efforts through centrally sponsored schemes under the National Health Mission (NHM). Programme funds are allocated based on state-specific Programme Implementation Plans and absorption capacity, with flexibility for states and Union Territories to use them according to local priorities.
Budget allocations for disease control programmes have increased in recent years. Funds approved under the National Disease Control Programme (NDCP) rose from Rs 4,062.69 crore in 2020-21 to Rs 5,542.18 crore in 2024-25, while allocations for the Non-Communicable Disease Control Programme (NP-NCD) increased from Rs 1,248.5 crore to Rs 4,107.96 crore during the same period.
Under the National Vector Borne Disease Control Programme, the government aims to eliminate malaria by 2030, with the target of zero indigenous cases by 2027. Between 2015 and 2025, malaria morbidity declined by 80.16 percent and mortality by 85.67 percent, according to provisional data.
India’s Annual Parasite Incidence dropped from 0.92 in 2015 to 0.17 in 2025, and 33 States and Union Territories now have an incidence rate below one case per thousand population, except Tripura, Mizoram and Odisha.
Mass drug administration coverage for lymphatic filariasis increased from 78 percent in 2015 to 85 percent in 2025, while the number of districts that discontinued mass drug administration after passing transmission assessment surveys rose from 41 to 143.
The Kala-azar elimination programme has achieved its threshold target of less than one case per 10,000 population across 633 endemic blocks in four states—Bihar, Jharkhand, West Bengal and Uttar Pradesh—since 2023.
The government reported that dengue cases fell by 48.19 percent in 2025 compared with 2024, while the case fatality rate remained 0.09 percent, well below the national target of under 1 percent.
For Japanese encephalitis, the case fatality rate declined from 17.6 percent in 2014 to 10.8 percent in 2025.
According to the World Health Organization’s Global TB Report 2025, India’s TB incidence rate fell by 21 percent, from 237 cases per lakh population in 2015 to 187 in 2024, while the mortality rate dropped by 25 percent, from 28 to 21 deaths per lakh population. Treatment coverage increased significantly from 53 percent in 2015 to 92 percent in 2024.
Under the National AIDS and STD Control Programme (NACP-V), India aims for the 95-95-95 targets—95 percent of people living with HIV knowing their status, 95 percent of those diagnosed receiving treatment, and 95 percent of those on treatment achieving viral suppression.
Nationally, HIV incidence declined from 0.06 in 2020 to 0.047 per thousand uninfected population in 2024, while AIDS-related mortality fell from 0.035 to 0.023 per thousand population. The number of people on anti-retroviral therapy increased from 13.88 lakh in March 2021 to 18.23 lakh by December 2025, a 31 percent rise.
The government informed Parliament that 770 district NCD clinics, 364 district day care cancer centres and 6,410 NCD clinics at community health centres have been established across the country. Screening for hypertension, diabetes and common cancers is being carried out through frontline health workers including Accredited Social Health Activists (ASHAs) and Auxiliary Nurse Midwives (ANMs) under the comprehensive primary healthcare system.
